Model-informed precision dosing (MIPD) has become synonymous with modern approaches for individualizing drug therapy, in which the characteristics of each patient are considered as opposed to applying a one-size-fits-all alternative. This review provides a brief account of the current knowledge, practices, and opinions on MIPD while defining an achievable vision for MIPD in clinical care based on available evidence. We begin with a historical perspective on variability in dose requirements and then discuss technical aspects of MIPD, including the need for clinical decision support tools, practical validation, and implementation of MIPD in health care. We also discuss novel ways to characterize patient variability beyond the common perceptions of genetic control. Finally, we address current debates on MIPD from the perspectives of the new drug development, health economics, and drug regulations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1146/annurev-pharmtox-033020-113257 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dose Optimization of Vancomycin in Pediatric Post-Cardiac Surgery Patients: A Population Pharmacokinetic Modeling Study.
Clin Pharmacokinet
December 2024
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
Background And Objective: Vancomycin is a glycopeptide antibiotic used for the treatment of severe gram-positive infections. Despite decades of clinical experience, optimized dosing for vancomycin in pediatric populations still warrants further investigation. Patients admitted to the pediatric intensive care unit (PICU) after cardiac surgery are often treated with vancomycin in case of (suspected) infection.
View Article and Find Full Text PDFModel-informed precision dosing of quetiapine in bipolar affective disorder patients: initial dose recommendation.
Front Psychiatry
December 2024
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy & School of Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Objective: Bipolar affective disorder (BAD) is a mood disorder with high morbidity and mortality. Quetiapine can be used in the treatment of patients with BAD; however, the precise administration regimen of quetiapine in these patients is still unknown. In this study, a population pharmacokinetic (PPK) model of quetiapine in patients with BAD was constructed based on model-informed precision dosing (MIPD) and real-world clinical data and an optimal initial dose of quetiapine in these patients was recommended.
View Article and Find Full Text PDFA PopPBPK-RL approach for precision dosing of benazepril in renal impaired patients.
J Pharmacokinet Pharmacodyn
December 2024
Research Center Pharmaceutical Engineering GmbH, 8010, Graz, Austria.
Current treatment recommendations mainly rely on rule-based protocols defined from evidence-based clinical guidelines, which are difficult to adapt for high-risk patients such as those with renal impairment. Consequently, unsuccessful therapies and the occurrence of adverse drug reactions are common. Within the context of personalized medicine, that tries to deliver the right treatment dose to maximize efficacy and minimize toxicity, the concept of model-informed precision dosing proposes the use of mechanistic models, like physiologically based pharmacokinetic (PBPK) modeling, to predict drug regimes outcomes.
View Article and Find Full Text PDFBarriers and Facilitators for Bringing Model-Informed Precision Dosing to the Patient's Bedside: A Systematic Review.
Clin Pharmacol Ther
December 2024
Division of Pharmacology and Toxicology, Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands.
Article Synopsis
- Model-informed precision dosing (MIPD) uses mathematical models to determine the best medication doses for individual patients, but challenges in its implementation prevent broader use in healthcare.
- A systematic review analyzed 15 articles to identify 72 barriers and facilitators impacting MIPD's integration, highlighting issues such as limited data for model validation and unclear regulatory guidelines.
- Key facilitators include the creation of user-friendly MIPD tools and collaborative efforts among stakeholders, along with educating healthcare providers to support MIPD in clinical settings.
Model-informed precision dosing in inflammatory bowel diseases.
Trends Pharmacol Sci
December 2024
Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Article Synopsis
- Therapeutic drug monitoring (TDM) for biologic therapies in inflammatory bowel disease (IBD) focuses on optimizing medication doses but faces challenges like identifying ideal drug levels and dealing with variability in drug response.
- Recent advancements, including population pharmacokinetic/pharmacodynamic (PK/PD) modeling and model-informed precision dosing (MIPD) tools, as well as point-of-care testing and new software, present promising solutions to these challenges.
- Implementing these innovations could lead to personalized dosing strategies, moving away from the current one-size-fits-all approach that doesn't meet the diverse needs of IBD patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!